X-Drug Conjugates (XDCs): The Next Generation of Targeted Therapeutics

Analytical Expertise in Conjugate Therapeutics: Blog 3

Author: Dr. Paola Grassi                                                                                                           Date: 18th February 2026
  

Introduction

The landscape of targeted therapeutics, until recently dominated by Antibody-Drug Conjugates (ADCs), has progressively advanced towards a new class of molecules: X-Drug Conjugates (XDCs).

XDCs represent an innovative approach designed to expand the range of therapeutic tools and improve precision in drug delivery. As the biopharma industry continues to focus on more effective, safer and personalised treatments, XDCs are emerging as a versatile solution that overcomes some of the limitations of existing platforms (1,2), allowing a wide variety of targeted ligands to be paired with different therapeutic payloads. XDCs offer an adaptable design, making them particularly well suited for addressing complex diseases that require selective tissue penetration, precise control of drug release and reduced off-target toxicity.

What Are XDCs?

X-Drug Conjugates (XDCs) combine a targeting moiety (the "X" component) with a bioactive drug payload via a chemical linker. Unlike traditional ADCs, the targeting moiety in XDCs can be an antibody fragment (F-DC), oligonucleotide (O-DC) (3), polymer (Po-DC) (4), peptide (P-DC) (5), aptamer (Ap-DC) (6) , small molecules (SM-DC) or others (7,8), enabling greater flexibility and more specific tissue or cell targeting (Figure 1).

Figure 1: Schematic Representation of XDC Classification.
Figure 1: Schematic Representation of XDC Classification.

In many ways, XDCs are at the cutting edge of precision medicine, combining the strengths of biologics and small molecules into a single smart therapeutic strategy (9).

Key Components of XDCs

  1. Carrier Moiety (X): This element determines the specificity of the conjugate. Using smaller ligands such as peptides or aptamers can allow for better tissue penetration and reduced immunogenicity compared to full-length antibodies.
  2. Linker Chemistry: The linker plays a pivotal role in the pharmacokinetics and release mechanism of the payload. Advances in cleavable and non-cleavable linker technologies have improved drug stability in circulation while ensuring payload release at the target site.
  3. Drug Payload: XDCs can carry a wide range of payloads, including cytotoxic agents, immunomodulators, radionuclides, or even nucleic acids, broadening the therapeutic potential beyond oncology.

Advantages of XDCs and Challenges

XDCs offer many advantages compared to traditional products, such as:

  • Enhanced Flexibility: The modular design of XDCs enables the use of diverse targeting ligands and payloads, allowing to adapt them to a wide range of therapeutic areas and disease targets.
  • Improved Tissue Penetration: Smaller targeting moieties allow XDCs to reach difficult-to-access tissues.
  • Expanded Therapeutic Applications: XDCs are not limited to oncology; they have potential in infectious diseases, autoimmune disorders, and gene therapy.
  • Optimized Pharmacokinetics: Linker and payload innovations contribute to better drug stability and controlled release.

Despite their promise, XDC development deals with challenges such as manufacturing complexity, optimization of linker stability, and difficulty in ensuring favourable safety profiles. Continued research is focusing on scalable synthesis methods, novel payload classes, and improved targeting strategies.

XDC Testing – strategies to overcome its complexity

While each XDC offers unique opportunities, they share one common feature: structural and analytical complexity. A thorough characterization is critical to ensure product quality, safety, and regulatory compliance (10).

To elucidate their complex structure, a combination of several analytical techniques can be employed:

  • Intact Mass Analysis (LC-MS/MS or MALDI-MS) – Confirms molecular weight and assess conjugation heterogeneity.
  • Peptide Mapping (LC-MS/MS) – Identifies conjugation sites, characterizes modifications, and ensures structural integrity.
  • Drug-to-X Ratio (DAX) Determination (LC-MS/MS)– Quantifies payload distribution with accuracy and reliability.
  • Glycosylation Profiling (LC-MS / LC-MS/MS, MALDI-MS) – Defines glycan structures to support stability, functionality, and regulatory approval.
  • Aggregate Analysis (SEC-MALS / AUC) – Determines the presence of aggregates or oligomers, which influences pharmacokinetics and toxicity.
  • HOS (Higher Order Structure) (CD, FTIR, 1D/2D NMR) – Assesses structural integrity and conformational changes induced by conjugation, crucial for stability, biological activity, and immunogenicity.
  • Solving Challenging Analytical Questions (ECD and cIMS-MS) – Detects epimers, resolves Leu/Ile isomer variants, and separates phosphorylated peptide or oligonucleotide isomers (11).

With its state-of-the-art analytical equipment, BioPharmaSpec we can provide a comprehensive suite of analytical solutions tailored for XDC development.

Conclusion

X-Drug Conjugates represent a significant leap in precision medicine, offering a versatile platform that bridges the gap between biologics and small molecules (12). Partnering with BioPharmaSpec can help accelerate XDC development while meeting the highest analytical and regulatory standards.

Advance Your XDC Program with Confidence

X-Drug Conjugates demand precise structural characterization and deep analytical expertise. BioPharmaSpec supports XDC developers with state-of-the-art mass spectrometry, higher-order structure analysis, and regulatory-ready data to accelerate development with confidence.

SPEAK TO A SCIENTIST